Skip to main content
Tianda Pharmaceuticals Limited logo

Tianda Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 455 HKEX Manufacturing
Open in API
Filings indexed 13 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 455

About Tianda Pharmaceuticals Limited

https://www.tiandapharma.com

Tianda Pharmaceuticals Limited is a specialty pharmaceutical enterprise engaged in the research, development, manufacturing, and sale of pharmaceutical, biotechnology, and healthcare products. The company focuses significantly on the Traditional Chinese Medicine (TCM) industrial chain, encompassing the cultivation of Chinese medicinal herbs, the production of decoction pieces, and the development of finished Chinese medicine products. Tianda Pharmaceuticals integrates modern technology, including artificial intelligence, into its TCM operations to enhance the entire industrial chain. The company also provides Chinese medicine clinical services and maintains R&D and production bases in mainland China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April, 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Tianda Pharmaceuticals Limited. It details movements in authorized and issued share capital, share options, and public float sufficiency confirmation. The document is a regulatory submission related to share capital and shareholding movements, not a financial report, earnings release, or management discussion. It is a regulatory filing specific to securities movements under HKEX rules, consistent with a regulatory filing (RNS) rather than a report or announcement of a report. The document length is 7,561 characters, which is substantive but the content is clearly a regulatory return rather than a financial or management report.
2026-05-06 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025
Environmental & Social Information Classification · 100% confidence The document is titled 'Environmental, Social and Governance Report 2025' and covers the period from January 1, 2025 to December 31, 2025. It explicitly states it is prepared in accordance with the ESG Reporting Code under the Listing Rules of the Hong Kong Stock Exchange. The content includes detailed ESG strategies, stakeholder engagement, materiality assessments, board statements on ESG responsibilities, and various environmental and social performance metrics. There is no indication that this is an announcement or a brief summary; rather, it is a comprehensive report on ESG performance and policies. Therefore, this document fits the category of Environmental & Social Information (ESG) report.
2026-04-29 English
Notification Letter and Request Form to Non-Registered Shareholders
Report Publication Announcement Classification · 90% confidence The document is a notification letter sent to non-registered shareholders informing them that the Company’s Annual Report 2025 and related circulars, AGM notice, and proxy form are available on its website and advising how to request printed copies. It does not contain the full report or financial data itself but merely announces the publication and provides instructions for access. This matches the definition of a Report Publication Announcement (RPA).
2026-04-29 English
Notification Letter and Reply Form to Registered Shareholders
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated 30 April 2026 from Tianda Pharmaceuticals Limited to its registered shareholders. It announces the publication of the Annual Report 2025, a circular related to general mandates for share repurchase and issuance, re-election of directors, re-appointment of auditor, and notice of the annual general meeting along with a proxy form. The letter directs shareholders to the company's website and the Stock Exchange website to access these documents electronically. It also includes a reply form for shareholders to choose their preferred method of receiving future corporate communications. The document does not contain the actual annual report or financial data but serves as a notice of publication and instructions for shareholders on how to access or receive the report and related materials. According to the "Menu vs Meal" rule, such a notification letter that informs about the availability of a report and provides access details without including the report itself should be classified as a Report Publication Announcement (RPA).
2026-04-29 English
Proxy form for use at the annual general meeting (the "AGM") of Tianda Pharmaceuticals Limited to be held on Friday, 12 June 2026 at 10:30 a.m. (or at any adjournment thereof)
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a proxy form used to appoint proxies and solicit votes ahead of the Annual General Meeting. It is part of the materials sent to shareholders to request votes on resolutions (e.g., re-election of directors, mandates). This aligns with the definition of Proxy Solicitation & Information Statement (PSI).
2026-04-29 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 75% confidence The document is the formal Notice of Annual General Meeting for Tianda Pharmaceuticals Limited, outlining the date, venue, agenda items (including financial statements, director elections, share repurchase and issuance mandates), and proxy voting instructions. It is an AGM notice rather than an actual financial report or voting results. This falls under "AGM Information (Code: AGM-R)" which covers materials related to convening or supporting the Annual General Meeting.
2026-04-29 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.